Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease

AstraZeneca280 enrolled

Overview

The purpose of this study is to determine whether treatment with 40mg of Rosuvastatin for 8 weeks will reduce the number of episodes of myocardial ischaemia suffered in subjects with coronary artery disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

280

Conditions

Myocardial Ischaemia Coronary Artery Disease

Interventions

RosuvastatinDRUG

Cholesterol lowering dietBEHAVIORAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Evidence of Coronary arterial disease * Suffering ischaemic episodes/exercise induced ischaemia * Not taking any cholesterol lowering medication Exclusion Criteria: * Unstable angina or heart attack less than one month before trial entry * Coronary arterial surgery as defined by protocol * Uncontrolled hypertension, diabetes, hypothyroidism or laboratory values as defined by the protocol.

Outcomes

Primary Outcomes

Number of episodes of myocardial ischaemia as assessed by ambulatory electrocardiographic monitoring.

Time frame: 8 weekly

Secondary Outcomes

Change in duration of ischemic episodes

Time frame: 8 weekly

Safety

Time frame: 8 weekly

Several laboratory parameters as detailed in the protocol

Time frame: 8 weekly

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.